NCT00293098View on ClinicalTrials.gov

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

APPROVED_FOR_MARKETINGEXPANDED_ACCESS
Timeline

Start Date

March 31, 2006

Conditions
Iron Overload
Interventions
DRUG

deferiprone

oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy

Trial Locations (1)

19104

The Children's Hospital of Philadelphia, Philadelphia

Sponsors

Collaborators (1)

ApoPharma
All Listed Sponsors
collaborator

ApoPharma

INDUSTRY

lead

Children's Hospital of Philadelphia

OTHER

NCT00293098 - Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease | Biotech Hunter | Biotech Hunter